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Abstract  
Introduction: The objective of the study was to identify the predictive factors for malignancy in pancreatic head mass as a primary outcome and 
assess the value of CA 19-9 as a diagnostic tool for malignancy as a secondary outcome.  
  
  
Methods 
A prospective study of patients presented with pancreatic head mass was conducted in a tertiary care referral hospital, Manipal, India from May 
2006 to November 2008. The study population was divided into malignant and benign groups based on the final histopathology report. A univariate 
and multivariate analysis of potential predictive factors for malignancy were conducted. Results: A total of 102 patients with pancreatic head mass 
were included in the study after fulfilling the inclusion/exclusion criteria. 78 were malignant and 24 were benign. There was significant weight loss 
(p<0.001) and high mean bilirubin levels (p=0.002) in the malignant group. Mean CA 19-9 was significantly higher in the malignant group (290.7 
vs. 30.3 U/ml; p<0.001). Sensitivity and specificity of CA 19-9 for detecting malignancy in pancreatic head mass at a cut off of 35U/ml was 86% 
and 79% respectively. CA 19-9 positivity rate was higher with increasing cut off values of 100, 200 and 300U/ml but such high levels occurred in 
fewer patients. All the non-jaundiced patients (100%) with raised CA 19-9 levels were found to be malignant compared to 86% malignancy in 
jaundiced patients. In multivariate analysis, a combination of weight loss > 10% of body weight and bilirubin > 3 mg/dl and CA 19-9 > 35U/ml 
had specificity and positive predictive value of 100% for predicting malignancy in pancreatic head mass. Conclusion: The presence of weight loss 
and jaundice and raised CA 19-9 levels together in a patient with pancreatic head mass can be predictive of malignancy. A very high CA 19-9 level 
can be an indicator of malignancy in a pancreatic head mass. A raised CA 19-9 level may be more predictive of malignancy in non-jaundiced 
patients than in jaundiced patients.  
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Introduction 
 
Pancreatic carcinoma accounts for only 2.6% of all newly diagnosed malignancies [1,2]. It is the ninth most common malignancy and fifth most 
common cause for cancer related deaths [3]. The overall 5-year disease-free survival rate is on the order of 1% to 2% [4]. Only 10% of patients 
have localized disease on presentation. Survival, however, is increased in those patients undergoing resection compared with those not undergoing 
surgery regardless of stage [5,6].  
  
The  morbidity  and  mortality  associated  with  pancreatic  head  resections  are  relatively  high  when  compared  with  distal  pancreatic  resections 
because  of  the  anatomical  location  of  the  head  of  pancreas  which  predisposes  to  infiltrate  adjacent  important  structures.  With  the  benign 
pancreatic masses closely mimicking malignancy, especially the chronic pancreatitis-inflammatory mass, accurate identification of malignancy in a 
pancreatic head mass is of utmost importance for early diagnosis and aggressive treatment of this lethal disease and also in avoiding a radical 
resection for a benign mass. We conducted a study to find the possible predictors of malignancy in a pancreatic head mass using clinical and 
biochemical parameters.  
  
  
Methods 
 
Study design  
  
A prospective study was conducted in Kasturba Hospital, Manipal, India from May 2006 to November 2008. The study group constituted patients 
admitted with a radiological diagnosis of pancreatic head mass. CA19-9 levels and a tissue diagnosis were obtained in all the patients. All the 
patients underwent Endoscopic retrograde cholangiopancreatogram (ERCP) brushings/cytology or/and Endoscopic ultarsonogram (EUS) -guided 
fine needle aspiration cytology (FNAC) as initial evaluation. This protocol was followed for a better loco-regional staging of the disease and also to 
identify conditions like lymphoma, endocrine tumors etc. that does not require radical pancreatic resections. The cytology/FNAC report divided the 
patients into one of the four arms -malignant, suspicious of malignancy, inconclusive, benign. All patients with radiologically resectable mass and 
FNAC  reported  as  malignant/suspicious  of  malignancy/inconclusive  underwent  surgical  exploration  and  resection.  Patients  with  radiologically 
unresectable mass and FNAC report as suspicious of malignancy and inconclusive were subjected to repeat FNAC. Lesions that failed to yield any 
results on repeat FNAC were subjected to open biopsy. All the patients in the benign arm were followed up by regular clinical visits and repeated 
imaging for a minimum of 12 months and those presented with progression of the disease were considered malignant and evaluated for resection. 
Patients with cystic neoplasm, mass body and tail of pancreas, endocrine tumors, recurrent tumors and, peri-ampullary tumors (Ampulla of Vater, 
Duodenal carcinoma, Distal CBD) were excluded to improve the validity of our result to solid pancreatic head mass alone. Patients in benign and 
malignant groups were compared for possible predictors of malignancy  
  
CA 19-9 measurement  
  
CA 19-9 was measured in 3ml of fresh serum obtained from peripheral venous sample. The kit used was ELISA for CA19-9 (Omega diagnostics co. 
Ltd., United Kingdom). The recommended cutoff value was 35 U/ml.  
  
Statistical analysis  
  
Patient demographics, risk factors, associated symptoms including weight loss, jaundice and CA 19-9 values were the variables compared between 
the  groups.  Multivariate  analysis  of  the  variables  was  also  performed  to  explore  the  possible  combinations  of  variables  that  could  predict 
malignancy.  
  
Statistical analysis  
  
Patient demographics, risk factors, associated symptoms including weight loss, jaundice and CA 19-9 values were the variables compared between 
the benign and malignant groups. Multivariate analysis was further performed for those variables that were significantly different between the two 
groups to explore a possible combination of variables could predict malignancy. Self reported or documented weight from prior medical visits was 
used in the estimation of weight loss. This may be subjected to recall error and subsequent error in calculation of the actual weight loss. However, 
self-reported weight has been shown to be accurate [7] and most epidemiological studies have used self-reported weight and weight change data 
[8,9]. Student – t test was used for comparing means of independent samples like age and weight loss. Chi square test was used to compare 
proportion like those of sex and weight loss. Wilcoxon rank sum test was used to compare means of ordinal variables like bilirubin and CA 19–9 
levels.  
  
Weight loss, jaundice and CA 19-9 levels were significantly different between the two groups and were further analyzed to find the optimal cut off 
that can predict malignancy with maximum yield. Conventional definition of clinically significant loss of more than 10% of body weight was used as 
a cut off for weight loss [10]. A Receiver Operating Characteristic (ROC) curve was used in the estimation of cut off values for Jaundice and CA 19-
9 levels. ROC curve is a commonly used and widely accepted statistical tool to establish cut off levels for a test [11]. Briefly, ROC curve is 
generated by plotting 1-specificity along x-axis and sensitivity along y-axis at different interpretation thresholds for a particular test. An ideal 
diagnostic test characterized by high true and low false positive rates will have a ROC curve upwards and to the left up corner close to the x-axis. 
In our study, cut off for bilirubin and CA 19-9 levels obtained by ROC were 3mg/dl and 35U/ml respectively.  
  
Further, Multivariate analysis was performed comparing the combination of weight loss more than 10%, bilirubin more than 3 mg/dl and CA 19 –9 
levels more than 35 U/ml between two groups. p-value < 0.05 is considered significant. Data analysis was done using SPSS software 11.0.1 
version.  Page number not for citation purposes  3 
  
Results 
 
Mode of tissue diagnosis  
  
Of 127 patients that were admitted during the study period, 102 patients were enrolled after fulfilling the inclusion criteria. After the initial ERCP 
brushings/cytology or/and EUS -guided FNAC, study population was divided into 51 malignant (group 1), 23 suspicious of malignancy (group 2), 13 
inconclusive (group 3) and 15 benign patients (group 4). Resection was attempted in 24 patients with radiologically resectable mass, of which 16 
cases had pre-operative report as malignant and 5 were suspicious of malignancy and 3 had an inconclusive report. Intraoperatively, 20 patients 
underwent Whipple’s pancreatico-duodenectomy and their final histopathology report of the resected specimen in four of the twenty patients 
showed  chronic  pancreatitis  with  benign  inflammatory  mass  while  the  remaining  16  cases  were  malignant.  Of  the  four  benign  cases  that 
underwent resection, three were preoperatively reported as suspicious of malignancy and one as inconclusive. All the 16 malignant cases were pre-
operatively reported as malignant. Four of the 24 patients who underwent resection were unresectable and hence surgical bypass and biopsy was 
performed. Final histopathology report of all the four unresectable mass was malignant. Repeat FNAC was performed in the remaining 18 cases in 
group 2 and 10 cases from group 3 with radiologically unresectable mass. After repeat FNAC, malignancy was reported in 15 out of 18 cases from 
group 2 and 4 out 10 cases from group 3 and four patients from group 3 were reported as benign. Remaining 3 cases from group 2 and two cases 
from group 3 were still inconclusive underwent open biopsy. Open biopsy revealed malignancy in 4 out of 5 cases and one case from group 3 was 
reported as benign. Ten patients in malignant arm with unresectable mass underwent surgery for drainage procedure as endoscopic drainage was 
unsuccessful / failed and a biopsy was performed during the surgery. None of the cases which were initially negative for malignancy in EUS guided 
FNAC presented with signs of malignancy on review during 12 months of follow up. Table 1 shows the mode of tissue diagnosis for all the patients 
included in the study.  
  
Single variable analysis  
  
In this study, the incidence and mean value of weight loss was significantly higher in the malignant group. The mean bilirubin and the CA19-9 
levels between the two groups were significantly higher in the malignant group (table 2). Mean CA 19-9 levels in patients with biliary obstruction 
was higher than patients without obstruction irrespective of benign or malignant mass (table 3). Demographics did not yield any statistical 
difference between two groups. Smoking and alcohol intake were present almost in equal proposition in both the groups. No statistical difference 
was  noted  in  the  presence  of  associated  diabetes  mellitus,  family  history  of  pancreatic  cancer,  associated  pain  abdomen  or  presence  of 
malabsorption.  
  
Receiver Operating Characteristics (ROC) Curve and cut off values  
  
Receiver Operating Characteristic (ROC) curve was employed for obtaining optimal cut off values for jaundice and CA 19-9 levels. ROC curve using 
different cut off values of these variables revealed a trade of between sensitivity and specificity for predicting malignancy. Figure 1 and 2 shows 
the ROC curves for these variables at different cut off values and it clearly indicates the optimal threshold for bilirubin level was 3mg/dl and CA 19-
9 was 35U/ml.  
  
The sensitivity, specificity of these variables for predicting malignancy when used alone was studied (table 4). CA 19-9 had the highest sensitivity 
(86%) of all the other variables. Sensitivity and specificity of CA19-9 at different cut off levels are shown in table 5. None of the three variables 
were effective in predicting malignancy individually.  
  
Jaundice and CA 19-9 levels  
  
Out of 72 patients with raised CA 19-9 levels, 43 were found to have jaundice while 29 were non-jaundiced. It was observed that all the 29 non-
jaundiced patients were malignant whereas 6 out 43 jaundiced patients were benign. Proportion of malignancy in jaundiced patients with raised CA 
19-9 levels was 86% and Proportion of malignancy in non-jaundiced patients with raised CA 19-9 levels was 100%. Moreover CA 19-9 positivity in 
malignant jaundiced patients was 97% and in non-malignant jaundiced patients was 85%.  
  
Multivariate analysis  
  
Sensitivity and specificity for predicting malignancy when any one/two variable/s was present in a patient is shown in table 6. Multivariate analysis 
demonstrated that all the 35 patients who had three variables present were malignant while none of the 24 benign patients had all the three 
variables present indicating a specificity and positive predictive value of 100% for detecting malignancy in pancreatic head mass (Table 6). 
Radiological evidence of malignancy was noted either in CT or ERCP or EUS in 32 out of 35 patients with all three variables present and none of 
the  24  benign  patients.  Hence  when  radiological  evidence  of  malignancy  was  included  in  the  multivariate  analysis  sensitivity  and  negative 
predictive value was reduced to 41% and 34% (Table 6).  
  
  
Discussion 
 
Univariate and Multivariate analysis  
  
In  our  study  demographics  were  comparable  between  the  benign  and  malignant  groups.  Apart  from  most  of  the  patients  (76/102)  with  a 
documented weight in prior hospital visits, we employed a self reported weight six months prior to the diagnosis of the mass in few patients 
(26/102). Weight loss, jaundice and CA 19-9 levels were the variables that were significantly higher in the malignant group.  Page number not for citation purposes  4 
  
We used ROC curve for the statistical analysis of bilirubin and CA 19-9 levels ROC curve has been extensively used by Hong-Ja Kim et al in their 
statistical analysis of CA 19-9 in various pancreatico-biliary diseases [12]. In our study, cut off for bilirubin and CA 19-9 levels obtained by ROC 
were 3mg/dl and 35U/ml respectively. Weight loss and CA 19-9 levels had almost similar sensitivity and specificity with jaundice with the lowest 
values. However these variables cannot be used individually to predict malignancy as their sensitivity and specificity were low. But when these 
three variables are present together in a patient with pancreatic head mass the specificity, positive predictive value were 100% for predicting 
malignancy. As far as our knowledge, Tessler et. al [13] were the first to correlate the clinical and biochemical parameters in combination to 
increase the efficiency of differentiating the malignant from benign lesions without a tissue diagnosis and their associated complications. A total of 
150 patients were studied by them, and established that weight loss and bilirubin levels were significantly higher in the malignant group. In 
multivariate analysis, a combination of weight loss >20 lbs, bilirubin >3 mg/dl, and CA 19-9 >37 U/ml had both a specificity and positive predictive 
value  of  100%  for  predicting  malignancy.  His  study  was  a  retrospective  study  based  on  data  collected  on  patients  operated  for  suspected 
pancreatic  malignancy,  which  includes  patients  with  pancreatic  mass  (head,  body  and  tail)  and  biliary  stricture  also.  In  our  study  we  have 
narrowed our patients to only pancreatic head mass, which is a common clinical scenario – pancreatic head mass – benign or malignant? The 
mean CA 19-9 levels in malignant and a benign group in our study was higher than Tessler et. al patients. This observation is possibly because 
Tessler has included body and tail mass, which are less likely to present with biliary obstruction and hence a lower value of CA 19-9 levels. 
Moreover CA 19-9 levels in our study are taken before biliary drainage of any form was attempted.  
  
CA 19-9 and Jaundice  
  
Other interesting observation of the study was the significance of raised CA 19-9 levels in jaundiced patients and non jaundiced patients with head 
mass. All the patients with raised CA 19-9 levels without jaundice were malignant whereas only 86% of the patients with jaundice were malignant. 
This implies the significance of raised CA 19-9 levels in non-jaundiced patients than in jaundiced patients with pancreatic head mass. CA 19-9 
antigen is synthesized both by the epithelial cells of the normal biliary tract and by the tumor cells and excreted within the bile [14]. It is suggested 
that the CA 19-9 antigen, which is high in concentration in the bile of the patients with benign and malignant obstructive jaundice, refluxes into the 
bloodstream due to the increase in the permeability between bile and blood, secondary to the bile stasis; moreover, it is stated that there can be 
an inability to degrade the antigen in the liver due to a hepatic dysfunction [15]. In the absence of obstructive jaundice the CA 19-9 present in the 
blood is exclusively by the tumor cells excluding the false positive possibility from the biliary tract epithelium. Hence a patient with pancreatic head 
mass without jaundice and raised CA 19-9 levels are more likely to be malignant than the jaundiced patients. Nuvit Duraker et al [16] in their study 
compared the CA 19-9 levels between benign and malignant pancreatic mass with and without jaundice also observed the similar importance of 
raised CA 19-9 levels in non-jaundiced patients. However, this observation did not attain statistical significance in our study and it requires further 
studies with more patients and carefully selected cohorts.  
  
CA 19-9 – Predictive Value  
  
Sensitivity and specificity of CA 19-9 for predicting malignancy in a patient with pancreatic head mass in our study was 86 and 79 respectively 
when the cut off value was 35U/ml. The values were comparable with other studies as shown in table 7. When the cut off values were raised to 
100, 200 and 300U/ml the positivity rate and specificity of CA 19-9 increased but such high values were seen only in fewer patients. At CA 19-9 
value of 300U/ml the specificity and positive predictive value were 100% for predicting malignancy (Table 5). Though there are isolated case 
reports of very high CA 19-9 levels in benign conditions [17] we can still consider it as an independent predictor of malignancy in the setting of the 
pancreatic mass lesion. This finding was also confirmed by Bedi et al in their study on mass lesions of chronic pancreatitis [18]. However, studies 
dedicated exclusively on very high CA 19-9 levels will help us in better understanding of this issue.  
  
  
Conclusion 
 
The clinical researches for the management of pancreatic carcinoma has been ever increasing to achieve early detection and deliver appropriate 
radical treatment to prolong the survival and also reducing the number of patients with benign mass undergoing inadvertent radical resection. 
Attempts are always being made in all possible ways to brighten this grey area – pancreatic head mass – benign or malignant? In our attempt we 
found that, under appropriate clinical circumstances, in a patient with pancreatic head mass, presence of weight loss and jaundice and raised CA 
19-9 levels can be predictive of malignancy and a radical resection should be considered even if the pre operative tissue diagnosis is not available. 
Very high CA 19-9 levels, though have occasionally been associated with benign conditions, were more specific for malignancy in the setting of a 
pancreatic head mass. Also, elevated levels of CA 19-9 have been found to predict malignancy better in non-jaundiced patients than in jaundiced 
patients but without reaching statistical significance. As our study was a retrospective review of prospectively selected cohort of patients, further 
prospective studies are required to validate the results of the study. In spite of these advances, the principle of pancreatic head mass management 
should still be radical resection for all pancreatic mass with suspicion of malignancy or inconclusive reports. The concerns of procedural morbidity 
and mortality for pancreatic mass that may ultimately be proved benign should not delay a radical resection for mass with suspicion of malignancy 
or inconclusive reports.  
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Table 1: Mode of tissue diagnosis for all the patients included in the study 
Mode of diagnosis  Malignant  Benign 
      
Resection/Open Biopsy  31  5 
Fine Needle Aspiration Cytology (FNAC)/Cytology  47  19 
  
 
 
 
 
Table 2: Variables that were compared between the two groups 
Variable  Malignant  Benign  P Value 
Age (years)  56.86 +/- 10.7  57.75 +/-15.2  0.810 
Proportion of male (%)  77.8  56.3  0.18 
Mean percent of weight loss (%)  17.4  4.3  <0.001 
Proportion of weight loss (%)  83.3  12.5  <0.001 
Mean bilirubin (mg/dl)  9.3  1.7  0.002 
CA 19-9 (u/ml)  290.8  30.3  <0.001 
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Table 3: Mean CA19-9 levels in malignant and benign patients with and without obstruction 
Mean ca 19-9 levels (u/ml)  Malignant  Benign 
      
With biliary obstruction 
  
402.9  47.5 
Without biliary obstruction  178.7  13.1 
        
  
 
 
Table 4: Univariate analysis of the three predictors studied 
Variable   Sensitivity %  Specificity %  PPV %  NPV % 
Weight loss (>10% in six months)  83  88  96  62 
Jaundice (>3mg/dl)  61  71  87  38 
CA 19-9 (>35U/ml)  86  79  93  63 
  
 
 
 
 
 
Table 5: Sensitivity and specificity of CA 19-9 in different cut off levels 
CA  19-9  cut  off  levels 
(U/ml) 
Benign  Malignant  Sensitivity %  Specificity % 
Normal  Increased  Normal  Increased 
          
   
37  19  5  11  67  86  79 
100  21  3  46  32  41  87 
200  23  1  60  18  23  96 
300  24  0  71  7  8  100 
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Table 6: Multivariate analysis of the three predictors studied 
Patients with pancreatic 
mass 
  
Sensitivity (%)  Specificity (%)  Positive 
predictive 
Value (%) 
Negative 
predictive 
Value (%) 
          
Weight  loss  >  10%  or  bilirubin  >  3  mg/dl  or 
raised CA 19-9 level > 35U/ml 
  
94  54  87  72 
Combination of any two variables present 
  
71  67  92  41 
Weight loss > 10% and bilirubin > 3 mg/dl and 
raised  CA  19-9  level  >35U/ml  with  radiological 
evidence of malignancy 
  
41  100  100  34 
Weight loss > 10% and bilirubin > 3 mg/dl and 
raised CA 19-9 level >35U/ml 
45  100  100  36 
              
 
 
 
 
 
Table 7: Comparison of the predictive value of CA19-9 
Author   Present Study  Nuvid Duraer et Al [16]  Cwik G et Al [19]  Goonetillek E Ks et Al [20] 
Year  2009  2007  2006  2007 
Type of the study  Prospective  Prospective  Prospective  Systematic Review 
Sensitivity (%)  86  81  81  79 
Specificity (%)  79  76  89  82 
Positive predictive Value (%)  93  77  93  81 
Negative Predictive Value (%)  63  80  89  80 
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